EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Putative azithromycin resistance mutations in Chlamydia trachomatis are globally distributed but arose before azithromycin was discovered

Parul Sharma iD, Deborah Dean iD, Timothy D Read iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01708-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Parul Sharma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Azithromycin, Chlamydia trachomatis, Drug Resistance, Bacterial, Anti-Bacterial Agents. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Azithromycin is widely used to treat Chlamydia trachomatis infections, yet the extent of resistance to the drug across the species has not been addressed. We surveyed mutations and substitutions linked to putative azithromycin resistance across 1,349 high-quality C. trachomatis genomes. Mutations in the rpl V gene encoding three non-synonymous substitutions, compared with the canonical C. trachomatis reference strain D//TW-3/Cx sequence, were found to be common but largely conserved within phylogenetic lineages causing prevalent urogenital and anorectal infections and lymphogranuloma venereum. However, no mutations were identified in the ocular lineage. Time-scaled phylogenetic analysis suggested that these mutations predate the clinical introduction of azithromycin. In contrast, no consistent resistance-associated patterns were observed in 23S rRNA or rpl D genes. This large-scale genomic surveillance provides critical insights into the evolutionary trends of putative azithromycin resistance in C. trachomatis and underscores the importance of integrating genomic monitoring with phenotypic susceptibility testing to accurately assess and manage antimicrobial resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinChlamydia trachomatisDrug Resistance, BacterialAnti-Bacterial AgentsMutationHumansRNA, Ribosomal, 23SPhylogenyMicrobial Sensitivity TestsChlamydia Infections

Stichwörter der Autor:innen

Chlamydia trachomatisantimicrobial resistanceazithromycingenomic surveillance

Substanzen

AzithromycinAnti-Bacterial AgentsRNA, Ribosomal, 23S

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Division of Infectious Diseases and Global Health, Departments of Medicine and Pediatrics, University of California San Francisco School of Medicine, San Francisco, California, USA.
  • Department of Bioengineering, Joint Program, University of California San Francisco and University of California Berkeley, San Francisco, California, USA.

ORCID-Profile: Parul Sharma, Deborah Dean, Timothy D Read

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Sharma, P., Dean, D., & Read, T. D. (2026). Putative azithromycin resistance mutations in Chlamydia trachomatis are globally distributed but arose before azithromycin was discovered. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01708-25

Vancouver

Sharma P, Dean D, Read TD. Putative azithromycin resistance mutations in Chlamydia trachomatis are globally distributed but arose before azithromycin was discovered. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01708-25

BibTeX
@article{Sharma2026,
  author = {Sharma, Parul and Dean, Deborah and Read, Timothy D},
  title = {Putative azithromycin resistance mutations in Chlamydia trachomatis are globally distributed but arose before azithromycin was discovered},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01708-25}
}
Kostenlos starten →